| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 221.80 | 15.1% | 14.4% |
| Total Income | 221.80 | 15.1% | 14.4% |
| Expenditure | 186.80 | 5.0% | 4.7% |
| PBT | 9.50 | 83.9% | 73.5% |
| Net Profit | -4.10 | 109.3% | 117.5% |
| OPM | 15.78% | 16.11pp | 8.51pp |
| NPM | -1.85% | 18.73pp | 10.92pp |
| EPS | -0.07 | 109.3% | 117.5% |
Embecta Corp. Reports Q2 FY26 Revenue of $221.8 Million, Down 14.4%
05 May 2026 · 5 May, 4:32 pm
Summary
Embecta Corp. reported a decrease in revenue for the second quarter of fiscal year 2026, with revenues of $221.8 million, down 14.4% compared to the prior year. The U.S. business was significantly impacted by increased competitive dynamics and softness in market volumes, while the international business performed in line with expectations. The company has initiated a review of its cost structure and organizational footprint in response to these results. Despite the revenue decline, Embecta expects to repay approximately $150 million in debt during 2026 and has authorized a share repurchase program.
Key Highlights
- 1
Embecta Corp. reported revenues of $221.8 million, a decrease of 14.4% compared to the prior year period.
- 2
U.S. revenues experienced a significant decrease of 29.4% on both a reported and adjusted constant currency basis.
- 3
International revenues showed a slight increase of 2.1% on a reported basis, but decreased by 4.1% on an adjusted constant currency basis.
- 4
The adjusted EBITDA was $64.6 million, with a margin of 29.1%, compared to $97.1 million and 37.5% in the prior year period.
- 5
The company announced a three-year share repurchase program of up to $100 million and a reduction in the quarterly cash dividend to $0.01 per share.
- 6
Embecta anticipates the acquisition of Owen Mumford to be completed during May 2026, which is expected to broaden the product portfolio.
- 7
The company updated its fiscal year 2026 revenue guidance to $1,015 - $1,035 million, reflecting a decrease of 6.1% - 4.2%.
Management Comments
Devdatt (Dev) Kurdikar
"We were disappointed with our second quarter results as they were significantly below our expectations, driven by a combination of factors which impacted our U.S. business, including increased competitive dynamics and softness in overall market volumes. Our International business performed in line with expectations." "Given our results, we have initiated a review of our cost structure and organizational footprint and expect to communicate findings and any resulting actions to investors once that process is complete. Our lowered financial guidance assumes that the dynamics which impacted our U.S. business during the second quarter will continue for the balance of the year, as well as the addition of Owen Mumford." "What gives us a constructive backdrop against which to manage through this period is the continued progress we are making in achieving important milestones on our strategic priorities and building embecta into a broader medical supplies company. On the strategic front, the pending acquisition of Owen Mumford remains on track to close during May 2026, following satisfaction of all closing conditions and regulatory approvals. This transaction will broaden our product portfolio beyond insulin injection delivery devices, significantly strengthen our B2B drug delivery platform, and it is consistent with the diversification strategy we presented at our 2025 Investor Day." "Despite the reduction in our revenue and profitability guidance ranges, we continue to expect to repay approximately $150 million in debt during 2026. We also adjusted our capital allocation framework this quarter, as our Board authorized a three-year share repurchase program of up to $100 million. Concurrently, we are reducing our quarterly cash dividend from $0.15 to $0.01 per share. Redirecting our regular dividend gives us increased flexibility to deploy capital towards share repurchases or additional debt reduction, consistent with our objective of long-term shareholder value creation."
Informational and educational content only. Not investment advice.